Back to top
more

Vanda Pharmaceuticals (VNDA)

(Delayed Data from NSDQ)

$4.88 USD

4.88
663,008

+0.20 (4.27%)

Updated May 3, 2024 04:00 PM ET

After-Market: $4.88 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag

by Zacks Equity Research

The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.

Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101

by Zacks Equity Research

Creative Medical's (CELZ) CELZ-101 gets FDA's Orphan Drug designation for preventing allograft rejection in type-I diabetes patients undergoing pancreatic islet cell transplantation. Stock rises.

Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia

by Zacks Equity Research

Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.

Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata

by Zacks Equity Research

The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.

Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat

by Zacks Equity Research

Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.

Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why

by Zacks Equity Research

Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.

Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates

by Zacks Equity Research

Puma Biotechnology's (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.

Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat

by Zacks Equity Research

Mirum's (MIRM) earnings fall shy of estimates in the fourth quarter of 2023 while revenues beat the same.

Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates

by Zacks Equity Research

Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.

Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks

by Zacks Equity Research

Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.

Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down

by Zacks Equity Research

Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues. Shares fall in after-hours trading.

Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates

by Zacks Equity Research

Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.

Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time. Stock rises.

Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update

by Zacks Equity Research

Intellia's (NTLA) earnings beat estimates in the fourth quarter while the company reports negative revenues. Management provides developmental and regulatory updates on its key pipeline candidates.

Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout

by Zacks Equity Research

Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.

Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y

by Zacks Equity Research

Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.

Earnings Estimates Moving Higher for Vanda (VNDA): Time to Buy?

by Zacks Equity Research

Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug

by Zacks Equity Research

The FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading.

Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of 100% and 12.78%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

After Plunging -7.98% in 4 Weeks, Here's Why the Trend Might Reverse for Vanda (VNDA)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Vanda (VNDA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Ekta Bagri headshot

5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.

Vanda Pharmaceuticals (VNDA) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of -40% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 24% and 1.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Investors Undervaluing Exelixis (EXEL) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Dynavax Technologies (DVAX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.